Kornimate/medical-research-clean huggingface dataset:
allogeneic hct using uniform conditioning regimen regardless of donors (ms, mu, or hf) for aml in remission

Conditions: Acute Myeloid Leukemia

Summary: the purpose of this study is to evaluate the effect of various clinical variables including hla-disparity and nk cell-related variables, upon outcomes of allogeneic hematopoietic cell transplantation (hct) using uniform conditioning regimen including busulfan, fludarabine, and antithymocyte globulin (atg) in patients with acute myeloid leukemia (aml) in the first complete remission (cr). the donors for allogeneic hct include hla-matched siblings, matched unrelated donors, and haploidentical family donors. therefore, the endpoints of the study are engraftment, secondary graft failure, acute and chronic graft-versus-host disease (gvhd), immune recovery, infections, leukemia recurrence, non-relapse mortality, and relapse-free (rfs) and overall survival (os) of patients.


Eligibility criteria:
inclusion criteria: * patients with non-promyelocytic aml (intermediate-risk or high-risk diseases by nccn guideline 2016) in the first cr * patients should be 16 years of age or more and 75 years of age or less * the performance status of the patients should be 70 or over by karnofsky performance scale * patients should have adequate hepatic function (bilirubin less than 2.0 mg/dl, ast less than three times the upper normal limit) * patients should have adequate renal function (creatinine less than 2.0 mg/dl) * patients should have adequate cardiac function (ejection fraction \> 40% on muga scan) * patients and stem cell donors must sign informed consent * for hematopoietic cell donor, if a patient has an hla-matched sibling (65 years or younger), that sibling will be a cell donor. if a patient does not have an hla-matched sibling but an hla-a, b, c, drb1 7-8/8 matched unrelated donor, the unrelated donor will be a cell donor. if a patient has neither hla-matched sibling nor unrelated donor, an hla-haploidentical familial donor will be a cell donor.

Keywords: aml cr allogeneic hematopoietic cell transplantation busulfan fludarabine atg
digital cognitive-behavioral therapy for insomnia for patients with multiple sclerosis

Conditions: Multiple Sclerosis; Insomnia

Summary: the goal of this clinical trialis to compare a digital cognitive-behavioral intervention for insomnia to digital administered applied relaxation in participants with multiple sclerosis. the treatments will be compared in following outcomes: * sleep diary: total sleep time (tst), sleep onset latency (sol), wake after sleep onset (waso), and early morning awakening (ema). * insomnia symptoms * depressive symptoms * client satisfaction * negative effects * worry * fatigue * quality of life * ms symptoms/function

in order to start evaluate the digital treatment format, this study will use a randomized controlled trial design (rct). participants with ms and insomnia from a neurology clinic in sweden will be randomized to either cognitive-behavioral intervention for insomnia (icbt) or applied relaxation (ar). the treatments will consits of six sessions and will be administered digitally. psychologists will have contact with the participants via a secure video call platform.follow-up data will be gathered at six and 12 months after the treatments. the treatments will be compared in following outcomes: * sleep diary: total sleep time (tst), sleep onset latency (sol), wake after sleep onset (waso), and early morning awakening (ema). * insomnia symptoms * depressive symptoms * worry * fatigue * quality of life * ms symptoms/function * client satisfaction * negative effects

Eligibility criteria:
inclusion criteria: * be medically assessed * meet criteria for ms and insomnia disorder * have access to the internet and a smart phone with internet access * have good reading ability, and * be over 18 years of age exclusion criteria: * have a planned treatment that may prevent participation * were involved in ongoing medical research that may prevent participation, * do not have a command of the swedish language * have a more serious acute psychiatric and/or somatic condition which prevented participation; or benefit from the treatment * have an increased risk of suicide to the extent that participation in study was considered inappropriate, * suffers from other primary sleep disorders such as sleep apnea, restless legs syndrome, periodic limb movement disorder, circadian rhythm disorder, or parasomnia * have insomnia due to environmental factors such as shift work.
phase 3 study of prostatak® immunotherapy with standard radiation therapy for localized prostate cancer

Conditions: Prostate Cancer

Summary: the purpose of this study is to evaluate the effectiveness of prostatak® immunotherapy in combination with radiation therapy for patients with intermediate-high risk localized prostate cancer. prostatak kills tumor cells and stimulates a cancer vaccine effect. killing tumor cells in an immune stimulatory environment induces the body's immune system to detect and destroy cancer cells. prostatak has shown synergy with radiation without added toxicity and lower than expected recurrence rates in previous clinical trials. the hypothesis is that prostatak can lead to improvement in the clinical outcome for patients with prostate cancer. participants will be randomized to the prostatak or control arm at a 2:1 ratio. both arms receive standard external beam radiation therapy. short-term androgen deprivation therapy may be given but is not required.


Eligibility criteria:
inclusion criteria include: * localized prostate cancer meeting the nccn criteria of intermediate risk or patients having only one nccn high-risk feature * nccn intermediate risk is defined as having at least one of the following: psa 10-20 ng/ml, gleason score =7, t2b-t2c * high risk with a single high risk feature is defined as having only one of the following: psa\>20 ng/ml, gleason score 8-10, or t3a * excluded are those in the following risk groups: low risk; high risk with more than 1 high risk factor; locally advanced/very high risk=t3b-t4; metastatic: n1 or m1 * planning to undergo standard prostate-only external beam radiation therapy * ecog performance status 0-2 exclusion criteria include: * liver disease, including known cirrhosis or active hepatitis * patients on systemic corticosteroids (\>10mg prednisone per day) or other immunosuppressive drugs * known hiv+ patients * regional lymph node involvement or distant metastases * patients planning to receive whole pelvic irradiation * prior treatment for prostate cancer, except turp or adt. for adt, it may only be given for a maximum of 6 months * patients who had or plan to have orchiectomy as the form of hormonal ablation * known sensitivity or allergic reactions to acyclovir or valacyclovir

Keywords: immunotherapy, cytotoxicity, tumor vaccine, prostate cancer, radiotherapy
mobilization with movement versus mulligan knee taping technique on patellofemoral pain syndrome.

Conditions: Patellofemoral Syndrome

Summary: this study intends to determine the effects of mwm verses mulligan knee taping on patellofemoral pain syndrome.

this is a single blinded randomized controlled trial, will be conducted at pakistan railway general hospital rawalpindi. both mwm and mulligan knee taping techniques are used in patients with patellofemoral pain syndrome. sample size of 34 individuals was calculated through open epi tool version 3 with 95 % confidence interval (ci), and power 80%. 34 individuals were screened out on the basis of inclusion and exclusion criteria. individuals of this selected population were randomly allocated as 17 individuals in mwm (straight leg raise with traction and tibial gliding) group and 17 individuals mulligan knee taping group by sealed envelope method. and after this both groups will receive conventional therapy. assesment will be done at baseline, 2nd week and after 6 weeks data will be analyzed on spss version 21.

Eligibility criteria:
inclusion criteria:• anterior knee pain durations lasting longer than two months, * pain scoring three or more according to numeric pain rating scale (nprs) during at least two activities * age between 20 and 45 years * both genders exclusion criteria: * • past history of total knee artthroplasty * intra articular steroid injection * rheumatoid arthritis * use of assistive devices e.g. canes, walkers and braces * knee injury

Keywords: anterior knee pain syndrome
a study of mk0663 and an approved drug in the treatment of osteoarthritis (0663-076)(completed)

Conditions: Osteoarthritis

Summary: the purpose of this study is to compare the safety and effectiveness of an investigational drug and an approved drug in the treatment of osteoarthritis of the knee and hip.

the duration of treatment is 26 weeks.

Eligibility criteria:
inclusion criteria: * osteoarthritis of the knee or hip which requires treatment with a medication to obtain pain relief exclusion criteria: * any known allergy to the study drugs

Keywords: arcoxia
low pressure pneumoperitoneum using airseal® for reduction in postoperative shoulder pain following robot assisted hiatal hernia repair

Conditions: Hernia, Hiatal; Pneumoperitoneum; Postoperative Pain; Shoulder Pain

Summary: the goal of this clinical trial is to evaluate the incidence and severity of post-operative shoulder pain following elective robot-assisted hiatal hernia repair in hopes of reducing pain and associated costs as well as clinic and emergency department visits due to this pain. you will undergo standard robot-assisted hiatal hernia repair with the standard postoperative care. the only difference is that you may be selected for the group where lower pressures used to fill your abdomen with carbon dioxide will be used, and you will be asked to fill out logs regarding your pain postoperatively. you will have postoperative appointments that are standard following this procedure.


Eligibility criteria:
inclusion criteria: * patients undergoing elective robot assisted hiatal hernia repair exclusion criteria: * patients less than 18 years of age * conversion to open surgery * bmi \> 40 * history of abdominoplasty * history of chronic pain and/or opioid dependence * history of copd and/or supplemental oxygen use * pregnant patients * incarcerated patients * patient refusal
a research study looking at how oral semaglutide works in people with type 2 diabetes in israel, as part of local clinical practice

Conditions: Diabetes Mellitus, Type 2

Summary: the purpose of the study is to collect information on how rybelsus® works in people with type 2 diabetes and to see if rybelsus® can lower their blood sugar levels. participants will get rybelsus® as prescribed to them by the study doctor. the study will last for about 8-10 months. participants will be asked to complete a questionnaire about how they take their rybelsus® tablets. participants will complete this questionnaire during their normally scheduled visit with the study doctor.


Eligibility criteria:
inclusion criteria: 1. signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol) 2. diagnosed with type 2 diabetes mellitus 3. the decision to initiate treatment with commercially available oral semaglutide has been made by the patient/legally acceptable representative (lar) and the specialist based on local label before and independently from the decision to include the patient in this study 4. male or female, age above or equal to 18 years at the time of signing informed consent 5. available hba1c value below or equal to 90 days prior to the 'informed consent and treatment initiation visit' (v1) or hba1c measurement taken in relation with the 'informed consent and treatment initiation visit' (v1) if in line with local clinical practice 6. treatment naïve to injectable glucose-lowering drug(s). an exception is short-term insulin treatment for acute illness for a total of below 14 days exclusion criteria: 1. previous participation in this study. participation is defined as having given informed consent in this study 2. treatment with any investigational drug within 30 days prior to enrolment into the study 3. mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
prediction of ibd disease activity in individual patients based on proms and clinical data

Conditions: IBD; Inflammatory Bone Disease

Summary: the proposed study will use a prom (patient report outcome measurement)-tool in combination with clinical and biochemical data to train and validate a relapse prediction model for individual patients.

the primary objective is to train and validate a relapse prediction model for individual patients available for daily (remote) care management. besides that, risk-based care pathways for different prediction outcomes will be evaluated, prediction scores will be correlated to medication type, crp/calprotectin and/or endoscopy, and with known ibd clinical risk profiles. moreover dietary intake will be correlated with the ibd risk profiles. study design: multicentre, retrospective analysis of two prospective cohorts. study population: adult ibd patients. main study parameters/endpoints: the endpoint will be a prediction regarding step-up or step-down in the care pathways. in other words, the percentage of patients in each individual care pathway with agreement between risk score of the individual patient and actual flares during a follow-up time of 24 months. furthermore insight will be gained in dietary patterns amongst patients with different ibd risk profiles. no benefits or risks are associated with participating in this study, because only standard of care is given.

Eligibility criteria:
inclusion criteria: * adult ibd patients * subjects willing and able to sign informed consent * own and are able to use a smart phone (android or ios) exclusion criteria: * unwilling or unable to adhere to the protocol * unwilling or unable to adhere to the informed consent * age \<18y
light stimulation to improve visual function after optic neuritis in persons with multiple sclerosis

Conditions: Multiple Sclerosis, Relapsing-Remitting; Optic Neuritis

Summary: the aim of this monocentric randomized controlled intervention study is to improve visual function in persons with multiple sclerosis following optic neuritis (neuritis nervi optici) by means of a light stimulation. in the treatment arm, two 80-second light stimulations are to be administered daily for 12 days in 25 persons with multiple sclerosis following recent optic neuritis (1-3 months). for the standardized application of light stimulation in the sense of standardized training, the light stimulation is to be carried out by watching a generated flicker video on a mobile phone. in a sham-intervened control group (sample size 25), the spontaneous course after optic neuritis will be recorded in parallel. intensive neuronal stimulation of the visual pathway will be used to stimulate regenerative processes, which will be recorded by means of changes in high-contrast visual acuity (primary endpoint). secondary endpoints are changes in a colored-contrast test, in 2.5% low contrast visual acuity, the peak conduction latency of visual evoked potentials, and retinal layer thicknesses and vessel densities measured in optical coherence tomography and optical coherence tomorgraphic angiography. these physiological parameters should help to understand the underlying processes of a potentially altered visual performance.


Eligibility criteria:
inclusion criteria: * relapsing remitting multiple sclerosis or clinically isolated syndrome or no indication of chronic inflammatory central nervous system disease * age 18-60 years * optic neuritis within 1-3 months exclusion criteria: * epilepsy * light-triggered migraine * insufficient vision correction * retinal disease (glaucoma, macular edema, macula degeneration, ...)
pembrolizumab administered via the sofusa® doseconnect™ in patients with relapsed/refractory cutaneous t-cell lymphoma.

Conditions: Mycosis Fungoides

Summary: in this pilot study, pembrolizumab will be administered via doseconnect in patient with relapsed or refractory cutaneous t-cell lymphoma to assess through pharmacodynamic assessment in the tumor tissue to assess if lymphatic delivery of pembrolizumab using sofusa doseconnect is feasible.

this is an open-label, single-center pilot study to investigate the pharmacodynamics, pharmacokinetics (pk), safety, and activity of pembrolizumab administered intra-lymphatically using the doseconnect in participants with relapsed or refractory cutaneous t-cell lymphoma (ctcl). all participants will receive the study intervention, pembrolizumab administered intralymphatically using the sofusa doseconnect device.

Eligibility criteria:
inclusion criteria: * confirmed diagnosis of one of mycosis fungoides (mf) * stage ib to iiib disease at screening * received at least 1 previous line of systemic therapy for ctcl. (participants with cd 30 positive mf must have received prior treatment with brentuximab vedotin.) * documented disease progression during or after the last therapy. * not previously treated with transplant and is ineligible for transplant * willing to undergo two biopsies during the study * 18 years or older at the time of signing informed consent form (icf) * adequate organ function * eastern cooperative oncology group (ecog) performance status of 0 or 1 * females of childbearing potential (fcbp) must agree to use a reliable form of contraceptive for the duration of the study and for at least 120 days (4 months) following the last dose of study intervention. * male participants must agree to use barrier contraception (i.e., condoms) for the duration of the study and for at least 120 days (4 months) following the last dose of study intervention exclusion criteria: * disease with extensive visceral or blood involvement. * previously treated with an anti-pd-l1 or anti-pd-1 antibody * any active autoimmune disease or a documented history of autoimmune disease, or history of syndrome that required systemic steroids or immunosuppressive medications, except for participants with vitiligo, hormone replacement therapy for stable thyroid diseases and type 1 diabetes mellitus. * prior allogeneic hematopoietic stem cell transplantation (hsct) or solid organ transplantation. * known seropositive for or have active infection with hepatitis c virus (hcv) or hepatitis b virus (hbv), or human immunodeficiency virus (hiv) * history of interstitial lung disease * history of severe hypersensitivity reactions to other monoclonal antibodies or known hypersensitivity to the study intervention or its excipients, indocyanine green dye or iodine. * known current drug or alcohol abuse. * pregnant or lactating. * underlying medical condition resulting in abnormally slow lymphatic flow as determined by the investigator. * require immediate treatment for mf

Keywords: ctcl cutaneous t-cell lymphoma mf/ss mycosis fungoides pembrolizumab pd-l1
adjunctive withania somnifera (ashwagandha) for persistent symptoms in people with schizophrenia

Conditions: Schizophrenia

Summary: to determine whether a standardized extract of withania somnifera will reduce psychopathology scores (panss total score) in persons with schizophrenia. a secondary aim is to determine whether wse reduces measures of positive and negative symptoms (panss subscales) and stress scores on the perceived stress scale (pss).


Eligibility criteria:
inclusion criteria: * diagnostic and statistical manual (dsm) 5 diagnosis of schizophrenia or schizoaffective disorder * ability to provide informed written consent * panss total score ≥ 70 or a cgi severity scored ≥ 4; and at least 2 positive symptom subscale items (i.e., delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, hostility and unusual thought content) scoring ≥ 4, or one of these items scoring ≥ 5, on a scale ranging from 1 = absent to 7 = extreme. * evidence of a positive symptom exacerbation during the year prior to study entry. * for women of child bearing age, a negative serum pregnancy test at screening exclusion criteria: * testing positive for illicit substances (positivity to marijuana or opioids will be assessed on a case by case basis due to the long elimination half life in the urine of marijuana and the use of opioids for various pain disorders, caffeine and nicotine are excepted) * receiving pharmacological treatment for addictions (naltrexone, suboxone, acamprosate, others) will be reviewed on a case by case basis * seriously unstable medical illnesses * pregnant or breast feeding women * known allergy or history of serious adverse event with wse * subjects who may require imminent hospitalization (examples: suicidal or aggressive behavior) * currently receiving antibiotics, anti-viral, or anti-parasitic medications * currently receiving immunosuppressive medications (e.g. oral scheduled corticosteroids, chemotherapy or transplantation or hiv/aids associated drugs).

Keywords: schizophrenia withania somnifera
hiv indicator diseases survey across europe - uk arm

Conditions: HIV; AIDS; Indicator Diseases/Indicator Conditions

Summary: in europe many patients infected with hiv remain undiagnosed, although this percentage varies between 15-80% across the continent. in the uk it is estimated to be 27%. undiagnosed hiv results in increased morbidity and mortality and reduced treatment response, as appropriate health interventions are delayed. it also has adverse public health implications, with those individuals unaware of their hiv status being more likely to transmit the virus. an important public health issue is how to diagnose more individuals with hiv earlier in the course of their infection. in the us, the centre for disease control and prevention (cdc) has introduced testing guidelines whereby all individuals are tested, unless they object, at any point of contact with the healthcare system - the "opt-out" testing guidelines. at the "hiv in europe" conference held in november 2007, the consensus, which included patient and public involvement, was that such an approach would not be suitable for europe. the conference recommended further development of focused hiv testing in patients presenting with certain clinical conditions and diseases - the "indicator disease'' testing guidelines. cost effectiveness analyses suggests cost savings if a screened population has an hiv prevalence of at least 1%, although this rate may be as low as 0.1%. however, there is very little - if any - evidence regarding hiv prevalence for certain conditions and diseases in specific and easy to identify sections of society. the focus of attention is on those conditions and diseases which occur more frequently in individuals known to be infected with hiv. the aim of this study is to assess hiv prevalence for several diseases and conditions, within a specific segment of the population not yet diagnosed with hiv, who present for care with that specific disease or condition. these conditions have been selected as they occur frequently in individuals already diagnosed with hiv infection. this is a pilot study to inform phase two, which will involve more diseases and conditions with a wider participation of centres across europe.


Eligibility criteria:
inclusion criteria * aged 16 years and over * presenting for care with one of the indicator diseases or conditions: * a sexually transmitted disease * malignant lymphoma * cervical or anal dysplasia or cancer * unexplained leukocytopenia or thrombocytopenia lasting at least 4 weeks, or hypergammaglobulinaemia * seborrheic dermatitis or exanthema * sub-study - consents to providing additional information exclusion criteria * known hiv positive * sub-study - declines to consent for additional information to be collected

Keywords: hiv testing targeted indicator diseases anal dysplasia cervical dysplasia sti lymphoma seborrhoeic dermatitis exanthema thrombocytpaenia lymphopaenia hypergammaglobulinaemia